Emili Masferrer i Niubò

Professor associat

Universitat de Vic - Universitat Central de Catalunya
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Background The relationship between hidradenitis suppurativa ( HS) and arthritis is well‐established; however, the impact of their combined disease burden and the associated treatment pattern has not been determined yet. This study aimed to assess disease burden and therapeutic approaches in HS patients with and without arthritis and estimate arthritis prevalence and subtypes. Methods A multicenter, retrospective, case–control study of 272 adults (69 with HS and arthritis; 203 with HS only), drawn from a hospital‐based cohort of 3644 HS patients across 10 Spanish centers. Controls were matched 1:3 by sex, age, and HS duration. Statistical analysis included non‐parametric tests, logistic regression, and linear mixed‐effects models adjusted for confounders. Results HS patients with arthritis had higher rates of immune‐mediated diseases, including inflammatory bowel disease (odds ratio [ OR] 9.44, p < 0.0001) and psoriasis ( OR 2.99, p = 0.0038), higher Dermatology Life Quality Index ( DLQI) scores (6.30 vs. 4.03, p = 0.031), more dermatology visits (7.00 vs. 5.00, p = 0.0077), and greater biologic therapy use (72.07% vs. 39.90%, p < 0.0001). The prevalence of arthritis among HS patients was 1.70% (95% confidence interval [ CI] : 1.00%–2.70%), with spondyloarthritis being the most common subtype (66.6%). Conclusions HS patients with arthritis have a greater disease burden and higher biologic therapy utilization, emphasizing the need for interdisciplinary care and optimizing resources.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (9)

Carla Ferrandiz-Pulido

Assitant Professor

University of Barcelona

SPAIN
View details

Patricia Garbayo-Salmons

Institute of Research and Innovation Parc Tauli

SPAIN
View details

Joan Calvet

Institute of Research and Innovation Parc Tauli

SPAIN
View details

Agustín Toll

-

SPAIN
View details

Roman Miñano - Medrano

Especialista colaborador

Hospital Universitario Fundación Jiménez Díaz

SPAIN
View details

Júlia Verdaguer-Faja

Universitat Autònoma de Barcelona

SPAIN
View details

Susana Puig

Head Dermatology Department

Hospital Clínic de Barcelona

SPAIN
View details

José C Pascual

-

SPAIN
View details

Alejandro Molina-Leyva

Head of Section

Hospital Universitario Virgen del Rocío

SPAIN
View details